In a report released today, Yaron Werber from Cowen & Co. maintained a Buy rating on Argenx Se (ARGX). The company’s shares closed last Monday at $124.89.
According to TipRanks.com, Werber is a 4-star analyst with an average return of 9.6% and a 58.6% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Prevail Therapeutics Inc.
Currently, the analyst consensus on Argenx Se is a Strong Buy with an average price target of $157.49.
See today’s analyst top recommended stocks >>
The company has a one-year high of $150.92 and a one-year low of $63.81. Currently, Argenx Se has an average volume of 140.3K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
argenx SE is a clinical-stage biotechnology company, which engages in the development of antibody-based therapies for the treatment of autoimmune diseases and cancer. Its products include ARGX-113 for the treatment of autoimmune disease myasthenia gravis and ARGX-110 for the treatment of hematological cancer acute myeloid leukemia.
